Ads
related to: current treatment for multiple sclerosis mayo clinicwexnermedical.osu.edu has been visited by 10K+ users in the past month
- World-class MS research
Research done here
to benefit MS patients
- Request an appointment
Schedule by phone
or online request
- Improving MS Outcomes
Leading the way
in care for MS patients
- MS Symptoms
Learn more about the
most common MS symptoms
- World-class MS research
doconsumer.com has been visited by 10K+ users in the past month
benchmarkguide.com has been visited by 10K+ users in the past month
alternativebee.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
In March 2017, ocrelizumab was approved in the United States for the treatment of primary progressive multiple sclerosis in adults. [22] [42] It is also used for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. [42]
Solitary sclerosis: This variant was proposed (2012) by Mayo Clinic researchers. [ 58 ] though it was also reported by other groups more or less at the same time. [ 59 ] [ 60 ] It is defined as isolated demyelinating lesions which produce a progressive myelopathy similar to primary progressive MS.
Multiple sclerosis (MS) is an autoimmune disease resulting in damage to the insulating covers of nerve cells in the brain and spinal cord. [3] As a demyelinating disease, MS disrupts the nervous system's ability to transmit signals, resulting in a range of signs and symptoms, including physical, mental, and sometimes psychiatric problems.
Research in multiple sclerosis may find new pathways to interact with the disease, improve function, curtail attacks, or limit the progression of the underlying disease. Many treatments already in clinical trials involve drugs that are used in other diseases or medications that have not been designed specifically for multiple sclerosis. There ...
Banwell is the co-director of the Pediatric Multiple Sclerosis and Neuroinflammatory Disorders Clinic at the Children's Hospital of Philadelphia. She has published extensively on pediatric demyelinating diseases including multiple sclerosis, neuromyelitis optica and MOG antibody disease.
Tumefactive multiple sclerosis is a condition in which the central nervous system of a person has multiple demyelinating lesions with atypical characteristics for those of standard multiple sclerosis (MS). It is called tumefactive as the lesions are "tumor-like" and they mimic tumors clinically, radiologically and sometimes pathologically.
Ads
related to: current treatment for multiple sclerosis mayo clinicwexnermedical.osu.edu has been visited by 10K+ users in the past month
doconsumer.com has been visited by 10K+ users in the past month
benchmarkguide.com has been visited by 10K+ users in the past month
alternativebee.com has been visited by 10K+ users in the past month